[Possibilities of Medical Correction of Moderate Cognitive Impairment.]

[Possibilities of medical correction of moderate cognitive impairment.]

Zh Nevrol Psikhiatr Im S S Korsakova. 2013; 113(2): 28-32
Bo?ko AN, Lebedeva AV, Shchukin IA, Soldatov MA, Ismailov AM, Shikhkerimov RK, Otcheskaia OV, Khozova AA

Thirty-four outpatients with moderate cognitive impairment were treated with one of standard extracts of Ginkgo Biloba – EGb761 (memoplant). Memoplant was used in high dosages (240 mg daily) twice a day during three months. Patients were assessed using the Montreal Cognitive Assessment (MoCA), the hospital depression scale and QoL questionnaire EQ5d as well as standard neurological and somatic examination. A statistical analysis of data revealed a significant improvement in most measures, mostly in attention, memory, orientation and visual-spatial/ executive functions as well as in anxiety and depression. The drug is well-tolerated and is recommended for practical use. HubMed – depression


[The combined therapy with valdoxan and amitriptyline of treatment resistant somatized depression.]

Zh Nevrol Psikhiatr Im S S Korsakova. 2013; 113(2): 20-24
Sobennikov VS, Prokop’eva ML

The combined treatment with valdoxan and amitriptyline has been suggested as one of the possible variants to overcome treatment resistance in somatized depression. A study design was based on the rhythmological model of depression which clinically characterized by altered sleep-awakeness cycles. According to this notion, 36 patients were divided into two groups by the presence (20 patients) or absence (16 patients) of severe sleep disorders. The combined treatment was more effective in the first group of patients with insomnia which was an indicator of altered sleep-awakeness cycles. HubMed – depression


[Anxiety-depressive disorders and cognitive impairment in patients of the primary level of health care.]

Zh Nevrol Psikhiatr Im S S Korsakova. 2013; 113(2): 14-19
Bobrov AE, Tsarenko DM, Kursakov AA, Dovzhenko TV

An objective of the study was to compare cognitive and anxiety-depressive disorders in patients of the primary level of health care. Authors studied 103 patients, mean age 51.2±15.9 years, of a psychotherapeutic setting in a polyclinic. Patients were stratified into three groups: patients with anxiety-depressive disorders (ADD), with mild organic mental disorders (MOMD) and with the combination of ADD and MOMD. Patients were assessed using a form for assessment of anxiety and depressive symptoms and psychometric scales HADS, MMSE, FAB, ACE-R. High positive correlations between the total score on the subscale “depression” of the HADS and some ACE-R items (total score, orientation/attention, verbal fluency) and total score on the FAB were identified in patients with ADD and MOMD compared to other groups. In patients with ADD, the correlations between some measures of cognitive style and language disturbances measured with the ACE-R were found. The results indicate that it is necessary to evaluate cognitive impairment (deficit symptoms and distortions in cognitive styles) in patients with anxiety-depressive disorders at the primary level of health care and to take it in account in choosing treatment options and predicting outcome. HubMed – depression



You must see!! acupuncture and depression treatment – visit http://tov1.net/depression1 acupuncture and depression treatment — With My Proven, Simple 3-Step Natural Formula YOU’LL: •Sleep better and wake up fee…